Aclaris Therapeutics, Inc. Fair Value, Assets, Level 2 to Level 1 Transfers, Amount
Aclaris Therapeutics, Inc. (ACRS) had Fair Value, Assets, Level 2 to Level 1 Transfers, Amount of $0 as of 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount · last filed 2022-02-24
- 2021-12-31: Fair Value, Assets, Level 2 to Level 1 Transfers, Amount $0.00.
- 2021-09-30: Fair Value, Assets, Level 2 to Level 1 Transfers, Amount $0.00.
- 2021-06-30: Fair Value, Assets, Level 2 to Level 1 Transfers, Amount $0.00.
- 2021-03-31: Fair Value, Assets, Level 2 to Level 1 Transfers, Amount $0.00.
| Period end | Fair Value, Assets, Level 2 to Level 1 Transfers, Amount |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-24 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-02 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-05 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-07 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-24 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-02 |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-05 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-07 |
| 2019-12-31 | $0.00 10-K · filed 2021-02-25 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-04 |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-07 |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-07 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-25 |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-06 |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-03 |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-08 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-18 |
| 2017-09-30 | $0.00 10-Q · filed 2017-11-07 |
| 2017-06-30 | $0.00 10-Q · filed 2017-08-08 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-09 |
| 2016-12-31 | $0.00 10-K · filed 2018-03-12 |
| 2016-09-30 | $0.00 10-Q · filed 2016-11-03 |
| 2016-06-30 | $0.00 10-Q · filed 2016-08-11 |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-11 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-15 |
| 2015-09-30 | $0.00 10-Q · filed 2015-12-03 |
| 2014-12-31 | $0.00 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |